Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Research Scholarships - Master's program

University of Toronto

$27,000.00

Linking Consensus Molecular Subtypes to the Tumour Immune Microenvironment in Biliary Tract Cancer

FY 2025-26

Summary
Bile duct cancer, or cholangiocarcinoma, is a rare but aggressive disease. Most patients are diagnosed at a late stage, and treatments such as surgery, chemotherapy, and immunotherapy often provide limited benefit. Bile duct cancer is not a single disease but rather a group of biologically distinct cancers with different genetic and molecular features. These differences may influence how the cancer grows and how it responds to treatment. Our research identified two major molecular subtypes of bile duct cancer: one marked by instability in the tumour’s DNA, and another driven by changes in how genes are regulated. While these subtypes help explain differences in tumour biology, we still do not understand how they relate to the body’s immune response. The immune system plays a central role in controlling cancer, and understanding how it behaves in each subtype may explain why some patients benefit from immunotherapy while others do not. We hypothesize that the DNA-unstable subtype has a broader and more variable immune response, while the gene-regulated subtype has a more limited or “quiet” immune environment. This project will examine the immune environment of bile duct cancers to determine how immune cells differ between the two molecular subtypes. Using advanced imaging and sequencing methods, we will measure the types of immune cells present in tumours and assess how these patterns relate to patient outcomes. We will also evaluate whether rapid molecular sequencing can accurately identify tumour subtypes soon after surgery. By linking tumour biology with the surrounding immune response, this research may help identify which patients are most likely to benefit from specific treatments and support more personalized and effective care for people with bile duct cancer.
Program
Master's Award: Canada Graduate Research Scholarships - Master's program
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
573128
Name
Arshinoff Danielle
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Linking Consensus Molecular Subtypes to the Tumour Immune Microenvironment in Biliary Tract Cancer
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Research Scholarships - Master's program
Keyworddelim
Adjuvant Therapy; Biliary Tract Cancer; Cholangiocarcinoma; Genomics; Immunotherapy; Neoadjuvant Therapy; Personalized Therapy; Surgery; Targeted Therapy; Treatment Optimization And Sequencing
Abstract
Bile duct cancer, or cholangiocarcinoma, is a rare but aggressive disease. Most patients are diagnosed at a late stage, and treatments such as surgery, chemotherapy, and immunotherapy often provide limited benefit. Bile duct cancer is not a single disease but rather a group of biologically distinct cancers with different genetic and molecular features. These differences may influence how the cancer grows and how it responds to treatment. Our research identified two major molecular subtypes of bile duct cancer: one marked by instability in the tumour’s DNA, and another driven by changes in how genes are regulated. While these subtypes help explain differences in tumour biology, we still do not understand how they relate to the body’s immune response. The immune system plays a central role in controlling cancer, and understanding how it behaves in each subtype may explain why some patients benefit from immunotherapy while others do not. We hypothesize that the DNA-unstable subtype has a broader and more variable immune response, while the gene-regulated subtype has a more limited or “quiet” immune environment. This project will examine the immune environment of bile duct cancers to determine how immune cells differ between the two molecular subtypes. Using advanced imaging and sequencing methods, we will measure the types of immune cells present in tumours and assess how these patterns relate to patient outcomes. We will also evaluate whether rapid molecular sequencing can accurately identify tumour subtypes soon after surgery. By linking tumour biology with the surrounding immune response, this research may help identify which patients are most likely to benefit from specific treatments and support more personalized and effective care for people with bile duct cancer.
Competitiondate
202512
Approvedterm2
1 yr 0 mth
Pinamesdelim
Arshinoff, Danielle
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~